Global Plasma Protein Therapeutics Market By Therapies (C1 esterase Inhibitors, Albumins, Immunoglobulins, Alpha-1 Proteinase Inhibitors, Coagulation Factors, Others); By Indication (Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Primary Immunodeficiency Disorder, Antithrombin III Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytpenic Purpura (ITP), Others, Hemophilia – Hemophilia A, Hemophilia B); By End User (Research Laboratories and Institutions, Hospitals, Blood Banks); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global plasma protein therapeutics market was valued at US$ 24.38 Bn in 2021, growing at an estimated CAGR of 7.6% over the forecast period (2022 – 2030). Medical science is integral part of human evolution and is still witnessing inventions that are truly magical. All this development should be credited to the continuous research activities across. Use of plasma protein is one such discovery that has been saving several numerous lives. While plasma is found in human blood and key part of human mechanism, protein happen to be one of the most important building blocks. The Plasma Protein Therapeutics have been a boon to the world as it is used to treat a range of diseases, including immune deficiencies, autoimmune and neurological disorders, hemophilia, infectious diseases, trauma, burns, and shock. This is why the global plasma protein therapeutics market has been taking giant strides.
Covid-19 Pandemic temporarily impacted plasma donation globally, affecting plasma protein therapeutics. However, due to lot of research focusing on plasma-based therapies during Covid-19 is anticipated to have a positive impact on the market. Moreover, the increase in the usage of therapeutic protein drugs in the treatment of a wide range of clinical symptoms is projected to generate a unique growth. All these factors helped the global plasma protein therapeutics market gain massive impetus while other markets were growing.
Therapies Outlook
Based on therapies, the global plasma protein therapeutics market has been divided into C1 esterase inhibitors, Albumins, Immunoglobulins, Alpha-1 Proteinase Inhibitors, Coagulation Factors, and others. The Albumin segment is expected to dominate in terms of market share. Albumin basically happens to be a simple type of protein, which coagulates after being exposed to heat and is easily soluble in water. As it is majorly found in the white part of egg, blood serum and milk, it is easier for body to absorb it.
Indication Outlook
Based on indication, the global plasma protein therapeutics market has been segmented as Alpha-1 Antitrypsin deficiency, Hereditary Angioedema, and Hemophilia, which is again bifurcated into two types i.e., hemophilia A and hemophilia B, Primary Immunodeficiency Disorder, Antithrombin III deficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytopenic Purpura (ITP), and others. While alpha-1 antitrypsin deficiency happens to be condition that puts one’s lungs and liver under threat, primary immunodeficiency disorder is where one’s total immunity is very low.
End User Outlook
Based on end-user, the global plasma protein therapeutics market has been divided into Research Laboratories and Institutions, Hospitals, and Blood Banks. The research laboratories and institutions generate maximum amount of revenue for this market. As full potential and uses of plasma proteins are yet to be discovered, many research institutes are conducting massive studies. On the other hand, the hospitals segment will witness growth at the fastest rate as plasma protein is already being used in the treatment of several diseases.
Region Outlook
On the basis of region, the global plasma protein therapeutics market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America mints maximum amount of money for this market. The healthcare sector in countries like the United States and Canada has been flourishing owing to top pharma and medical research companies. Federal governments and regulators have also granted authorization to the use of plasma protein.
Global Plasma Protein Therapeutics Market Revenue & Forecast, (US$ Million), 2022 – 2030
Competitive Landscape
The report provides both, qualitative and quantitative research of the global plasma protein therapeutics market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the major players operating in the global plasma protein therapeutics market are listed below:
- ADMA biologics, Inc.
- Baxter International
- Biotest
- China Biologics
- CSL
- GRIFOLS, S.A.
- Kedrion
- Octapharma USA, Inc.
- Takeda Pharmaceutical Company Ltd
- Other Market Participants
Global Plasma Protein Therapeutics Market
By Therapies
- C1 esterase Inhibitors
- Albumins
- Immunoglobulins
- Alpha-1 Proteinase Inhibitors
- Coagulation Factors
- Others
By Indication
- Alpha-1 Antitrypsin Deficiency
- Hereditary Angioedema
- Hemophilia
- Hemophilia A
- Hemophilia B
- Primary Immunodeficiency Disorder
- Antithrombin III Deficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
By End User
- Research Laboratories and Institutions
- Hospitals
- Blood Banks
By Region
- North America
- S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2022
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Plasma Protein Therapeutics Market
6. Market Synopsis: Plasma Protein Therapeutics Market
7. Plasma Protein Therapeutics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Plasma Protein Therapeutics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Plasma Protein Therapeutics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Plasma Protein Therapeutics Market
8. Global Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Plasma Protein Therapeutics Market Revenue (US$ Mn)
8.2. Global Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
8.2.1. C1 esterase Inhibitors
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Albumins
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Immunoglobulins
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Alpha-1 Proteinase Inhibitors
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 – 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. Coagulation Factors
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2021
8.2.5.3. Market Forecast, 2022 – 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.2.6. Others
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2021
8.2.6.3. Market Forecast, 2022 – 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 – 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 – 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 – 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 – 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Therapies
9. Global Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
9.2.1. Alpha-1 Antitrypsin Deficiency
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Hereditary Angioedema
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Hemophilia (Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Hemophilia A, Hemophilia B)
9.2.3.1. Hemophilia A
9.2.3.2. Hemophilia B
9.2.4. Primary Immunodeficiency Disorder
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 – 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Antithrombin III Deficiency
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 – 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 – 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 – 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 – 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 – 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 – 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 – 2030
9.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 – 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market Estimation, 2015 - 2021
9.2.7.5.1.2. Market Forecast, 2022 – 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2021
9.2.7.5.2.2. Market Forecast, 2022 – 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2021
9.2.7.5.3.2. Market Forecast, 2022 – 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2021
9.2.7.5.4.2. Market Forecast, 2022 – 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market Estimation, 2015 - 2021
9.2.7.5.5.2. Market Forecast, 2022 – 2030
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 – 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market Estimation, 2015 - 2021
9.2.8.5.1.2. Market Forecast, 2022 – 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market Estimation, 2015 - 2021
9.2.8.5.2.2. Market Forecast, 2022 – 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market Estimation, 2015 - 2021
9.2.8.5.3.2. Market Forecast, 2022 – 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market Estimation, 2015 - 2021
9.2.8.5.4.2. Market Forecast, 2022 – 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market Estimation, 2015 - 2021
9.2.8.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Indication
10. Global Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
10.2.1. Research Laboratories and Institutions
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Hospitals
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Blood Banks
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End User
11. North America Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.1.1. North America Plasma Protein Therapeutics Market Revenue (US$ Mn)
11.2. North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
11.2.1. C1 esterase Inhibitors
11.2.2. Albumins
11.2.3. Immunoglobulins
11.2.4. Alpha-1 Proteinase Inhibitors
11.2.5. Coagulation Factors
11.2.6. Others
11.3. North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
11.3.1. Alpha-1 Antitrypsin Deficiency
11.3.2. Hereditary Angioedema
11.3.3. Hemophilia
11.3.3.1. Hemophilia A
11.3.3.2. Hemophilia B
11.3.4. Primary Immunodeficiency Disorder
11.3.5. Antithrombin III Deficiency
11.3.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.7. Idiopathic Thrombocytpenic Purpura (ITP)
11.3.8. Others
11.4. North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
11.4.1. Research Laboratories and Institutions
11.4.2. Hospitals
11.4.3. Blood Banks
11.5. North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
11.5.1.1.1. C1 esterase Inhibitors
11.5.1.1.2. Albumins
11.5.1.1.3. Immunoglobulins
11.5.1.1.4. Alpha-1 Proteinase Inhibitors
11.5.1.1.5. Coagulation Factors
11.5.1.1.6. Others
11.5.1.2. U.S Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.1.2.1. Alpha-1 Antitrypsin Deficiency
11.5.1.2.2. Hereditary Angioedema
11.5.1.2.3. Hemophilia
11.5.1.2.3.1. Hemophilia A
11.5.1.2.3.2. Hemophilia B
11.5.1.2.4. Primary Immunodeficiency Disorder
11.5.1.2.5. Antithrombin III Deficiency
11.5.1.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.5.1.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
11.5.1.2.8. Others
11.5.1.3. U.S Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.1.3.1. Research Laboratories and Institutions
11.5.1.3.2. Hospitals
11.5.1.3.3. Blood Banks
11.5.2. Canada
11.5.2.1. Canada Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
11.5.2.1.1. C1 esterase Inhibitors
11.5.2.1.2. Albumins
11.5.2.1.3. Immunoglobulins
11.5.2.1.4. Alpha-1 Proteinase Inhibitors
11.5.2.1.5. Coagulation Factors
11.5.2.1.6. Others
11.5.2.2. Canada Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.2.2.1. Alpha-1 Antitrypsin Deficiency
11.5.2.2.2. Hereditary Angioedema
11.5.2.2.3. Hemophilia
11.5.2.2.3.1. Hemophilia A
11.5.2.2.3.2. Hemophilia B
11.5.2.2.4. Primary Immunodeficiency Disorder
11.5.2.2.5. Antithrombin III Deficiency
11.5.2.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.5.2.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
11.5.2.2.8. Others
11.5.2.3. Canada Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.2.3.1. Research Laboratories and Institutions
11.5.2.3.2. Hospitals
11.5.2.3.3. Blood Banks
11.5.3. Mexico
11.5.3.1. Mexico Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
11.5.3.1.1. C1 esterase Inhibitors
11.5.3.1.2. Albumins
11.5.3.1.3. Immunoglobulins
11.5.3.1.4. Alpha-1 Proteinase Inhibitors
11.5.3.1.5. Coagulation Factors
11.5.3.1.6. Others
11.5.3.2. Mexico Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.3.2.1. Alpha-1 Antitrypsin Deficiency
11.5.3.2.2. Hereditary Angioedema
11.5.3.2.3. Hemophilia
11.5.3.2.3.1. Hemophilia A
11.5.3.2.3.2. Hemophilia B
11.5.3.2.4. Primary Immunodeficiency Disorder
11.5.3.2.5. Antithrombin III Deficiency
11.5.3.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.5.3.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
11.5.3.2.8. Others
11.5.3.3. Mexico Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.3.3.1. Research Laboratories and Institutions
11.5.3.3.2. Hospitals
11.5.3.3.3. Blood Banks
11.5.4. Rest of North America
11.5.4.1. Rest of North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
11.5.4.1.1. C1 esterase Inhibitors
11.5.4.1.2. Albumins
11.5.4.1.3. Immunoglobulins
11.5.4.1.4. Alpha-1 Proteinase Inhibitors
11.5.4.1.5. Coagulation Factors
11.5.4.1.6. Others
11.5.4.2. Rest of North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.4.2.1. Alpha-1 Antitrypsin Deficiency
11.5.4.2.2. Hereditary Angioedema
11.5.4.2.3. Hemophilia
11.5.4.2.3.1. Hemophilia A
11.5.4.2.3.2. Hemophilia B
11.5.4.2.4. Primary Immunodeficiency Disorder
11.5.4.2.5. Antithrombin III Deficiency
11.5.4.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.5.4.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
11.5.4.2.8. Others
11.5.4.3. Rest of North America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1. Research Laboratories and Institutions
11.5.4.3.2. Hospitals
11.5.4.3.3. Blood Banks
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Therapies
11.6.3. By Indication
11.6.4. By End User
12. Europe Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. Europe Plasma Protein Therapeutics Market Revenue (US$ Mn)
12.2. Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.2.1. C1 esterase Inhibitors
12.2.2. Albumins
12.2.3. Immunoglobulins
12.2.4. Alpha-1 Proteinase Inhibitors
12.2.5. Coagulation Factors
12.2.6. Others
12.3. Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.3.1. Alpha-1 Antitrypsin Deficiency
12.3.2. Hereditary Angioedema
12.3.3. Hemophilia
12.3.3.1. Hemophilia A
12.3.3.2. Hemophilia B
12.3.4. Primary Immunodeficiency Disorder
12.3.5. Antithrombin III Deficiency
12.3.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.3.8. Others
12.4. Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.4.1. Research Laboratories and Institutions
12.4.2. Hospitals
12.4.3. Blood Banks
12.5. Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.1.1.1. C1 esterase Inhibitors
12.5.1.1.2. Albumins
12.5.1.1.3. Immunoglobulins
12.5.1.1.4. Alpha-1 Proteinase Inhibitors
12.5.1.1.5. Coagulation Factors
12.5.1.1.6. Others
12.5.1.2. France Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.1.2.1. Alpha-1 Antitrypsin Deficiency
12.5.1.2.2. Hereditary Angioedema
12.5.1.2.3. Hemophilia
12.5.1.2.3.1. Hemophilia A
12.5.1.2.3.2. Hemophilia B
12.5.1.2.4. Primary Immunodeficiency Disorder
12.5.1.2.5. Antithrombin III Deficiency
12.5.1.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.1.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.1.2.8. Others
12.5.1.3. France Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1.3.1. Research Laboratories and Institutions
12.5.1.3.2. Hospitals
12.5.1.3.3. Blood Banks
12.5.2. The UK
12.5.2.1. The UK Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.2.1.1. C1 esterase Inhibitors
12.5.2.1.2. Albumins
12.5.2.1.3. Immunoglobulins
12.5.2.1.4. Alpha-1 Proteinase Inhibitors
12.5.2.1.5. Coagulation Factors
12.5.2.1.6. Others
12.5.2.2. The UK Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.2.2.1. Alpha-1 Antitrypsin Deficiency
12.5.2.2.2. Hereditary Angioedema
12.5.2.2.3. Hemophilia
12.5.2.2.3.1. Hemophilia A
12.5.2.2.3.2. Hemophilia B
12.5.2.2.4. Primary Immunodeficiency Disorder
12.5.2.2.5. Antithrombin III Deficiency
12.5.2.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.2.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.2.2.8. Others
12.5.2.3. The UK Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.2.3.1. Research Laboratories and Institutions
12.5.2.3.2. Hospitals
12.5.2.3.3. Blood Banks
12.5.3. Spain
12.5.3.1. Spain Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.3.1.1. C1 esterase Inhibitors
12.5.3.1.2. Albumins
12.5.3.1.3. Immunoglobulins
12.5.3.1.4. Alpha-1 Proteinase Inhibitors
12.5.3.1.5. Coagulation Factors
12.5.3.1.6. Others
12.5.3.2. Spain Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.3.2.1. Alpha-1 Antitrypsin Deficiency
12.5.3.2.2. Hereditary Angioedema
12.5.3.2.3. Hemophilia
12.5.3.2.3.1. Hemophilia A
12.5.3.2.3.2. Hemophilia B
12.5.3.2.4. Primary Immunodeficiency Disorder
12.5.3.2.5. Antithrombin III Deficiency
12.5.3.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.3.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.3.2.8. Others
12.5.3.3. Spain Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.3.3.1. Research Laboratories and Institutions
12.5.3.3.2. Hospitals
12.5.3.3.3. Blood Banks
12.5.4. Germany
12.5.4.1. Germany Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.4.1.1. C1 esterase Inhibitors
12.5.4.1.2. Albumins
12.5.4.1.3. Immunoglobulins
12.5.4.1.4. Alpha-1 Proteinase Inhibitors
12.5.4.1.5. Coagulation Factors
12.5.4.1.6. Others
12.5.4.2. Germany Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.4.2.1. Alpha-1 Antitrypsin Deficiency
12.5.4.2.2. Hereditary Angioedema
12.5.4.2.3. Hemophilia
12.5.4.2.3.1. Hemophilia A
12.5.4.2.3.2. Hemophilia B
12.5.4.2.4. Primary Immunodeficiency Disorder
12.5.4.2.5. Antithrombin III Deficiency
12.5.4.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.4.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.4.2.8. Others
12.5.4.3. Germany Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.4.3.1. Research Laboratories and Institutions
12.5.4.3.2. Hospitals
12.5.4.3.3. Blood Banks
12.5.5. Italy
12.5.5.1. Italy Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.5.1.1. C1 esterase Inhibitors
12.5.5.1.2. Albumins
12.5.5.1.3. Immunoglobulins
12.5.5.1.4. Alpha-1 Proteinase Inhibitors
12.5.5.1.5. Coagulation Factors
12.5.5.1.6. Others
12.5.5.2. Italy Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.5.2.1. Alpha-1 Antitrypsin Deficiency
12.5.5.2.2. Hereditary Angioedema
12.5.5.2.3. Hemophilia
12.5.5.2.3.1. Hemophilia A
12.5.5.2.3.2. Hemophilia B
12.5.5.2.4. Primary Immunodeficiency Disorder
12.5.5.2.5. Antithrombin III Deficiency
12.5.5.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.5.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.5.2.8. Others
12.5.5.3. Italy Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.5.3.1. Research Laboratories and Institutions
12.5.5.3.2. Hospitals
12.5.5.3.3. Blood Banks
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.6.1.1. C1 esterase Inhibitors
12.5.6.1.2. Albumins
12.5.6.1.3. Immunoglobulins
12.5.6.1.4. Alpha-1 Proteinase Inhibitors
12.5.6.1.5. Coagulation Factors
12.5.6.1.6. Others
12.5.6.2. Nordic Countries Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.6.2.1. Alpha-1 Antitrypsin Deficiency
12.5.6.2.2. Hereditary Angioedema
12.5.6.2.3. Hemophilia
12.5.6.2.3.1. Hemophilia A
12.5.6.2.3.2. Hemophilia B
12.5.6.2.4. Primary Immunodeficiency Disorder
12.5.6.2.5. Antithrombin III Deficiency
12.5.6.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.6.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.6.2.8. Others
12.5.6.3. Nordic Countries Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1. Research Laboratories and Institutions
12.5.6.3.2. Hospitals
12.5.6.3.3. Blood Banks
12.5.6.4. Nordic Countries Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.7.1.1. C1 esterase Inhibitors
12.5.7.1.2. Albumins
12.5.7.1.3. Immunoglobulins
12.5.7.1.4. Alpha-1 Proteinase Inhibitors
12.5.7.1.5. Coagulation Factors
12.5.7.1.6. Others
12.5.7.2. Benelux Union Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.7.2.1. Alpha-1 Antitrypsin Deficiency
12.5.7.2.2. Hereditary Angioedema
12.5.7.2.3. Hemophilia
12.5.7.2.3.1. Hemophilia A
12.5.7.2.3.2. Hemophilia B
12.5.7.2.4. Primary Immunodeficiency Disorder
12.5.7.2.5. Antithrombin III Deficiency
12.5.7.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.7.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.7.2.8. Others
12.5.7.3. Benelux Union Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1. Research Laboratories and Institutions
12.5.7.3.2. Hospitals
12.5.7.3.3. Blood Banks
12.5.7.4. Benelux Union Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
12.5.8.1.1. C1 esterase Inhibitors
12.5.8.1.2. Albumins
12.5.8.1.3. Immunoglobulins
12.5.8.1.4. Alpha-1 Proteinase Inhibitors
12.5.8.1.5. Coagulation Factors
12.5.8.1.6. Others
12.5.8.2. Rest of Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.8.2.1. Alpha-1 Antitrypsin Deficiency
12.5.8.2.2. Hereditary Angioedema
12.5.8.2.3. Hemophilia
12.5.8.2.3.1. Hemophilia A
12.5.8.2.3.2. Hemophilia B
12.5.8.2.4. Primary Immunodeficiency Disorder
12.5.8.2.5. Antithrombin III Deficiency
12.5.8.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.5.8.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
12.5.8.2.8. Others
12.5.8.3. Rest of Europe Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
12.5.8.3.1. Research Laboratories and Institutions
12.5.8.3.2. Hospitals
12.5.8.3.3. Blood Banks
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Therapies
12.6.3. By Indication
12.6.4. By End User
13. Asia Pacific Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn)
13.2. Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.2.1. C1 esterase Inhibitors
13.2.2. Albumins
13.2.3. Immunoglobulins
13.2.4. Alpha-1 Proteinase Inhibitors
13.2.5. Coagulation Factors
13.2.6. Others
13.3. Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.3.1. Alpha-1 Antitrypsin Deficiency
13.3.2. Hereditary Angioedema
13.3.3. Hemophilia
13.3.3.1. Hemophilia A
13.3.3.2. Hemophilia B
13.3.4. Primary Immunodeficiency Disorder
13.3.5. Antithrombin III Deficiency
13.3.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.3.8. Others
13.4. Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.4.1. Research Laboratories and Institutions
13.4.2. Hospitals
13.4.3. Blood Banks
13.5. Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.1.1.1. C1 esterase Inhibitors
13.5.1.1.2. Albumins
13.5.1.1.3. Immunoglobulins
13.5.1.1.4. Alpha-1 Proteinase Inhibitors
13.5.1.1.5. Coagulation Factors
13.5.1.1.6. Others
13.5.1.2. China Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.1.2.1. Alpha-1 Antitrypsin Deficiency
13.5.1.2.2. Hereditary Angioedema
13.5.1.2.3. Hemophilia
13.5.1.2.3.1. Hemophilia A
13.5.1.2.3.2. Hemophilia B
13.5.1.2.4. Primary Immunodeficiency Disorder
13.5.1.2.5. Antithrombin III Deficiency
13.5.1.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.1.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.1.2.8. Others
13.5.1.3. China Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1.3.1. Research Laboratories and Institutions
13.5.1.3.2. Hospitals
13.5.1.3.3. Blood Banks
13.5.2. Japan
13.5.2.1. Japan Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.2.1.1. C1 esterase Inhibitors
13.5.2.1.2. Albumins
13.5.2.1.3. Immunoglobulins
13.5.2.1.4. Alpha-1 Proteinase Inhibitors
13.5.2.1.5. Coagulation Factors
13.5.2.1.6. Others
13.5.2.2. Japan Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.2.2.1. Alpha-1 Antitrypsin Deficiency
13.5.2.2.2. Hereditary Angioedema
13.5.2.2.3. Hemophilia
13.5.2.2.3.1. Hemophilia A
13.5.2.2.3.2. Hemophilia B
13.5.2.2.4. Primary Immunodeficiency Disorder
13.5.2.2.5. Antithrombin III Deficiency
13.5.2.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.2.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.2.2.8. Others
13.5.2.3. Japan Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.2.3.1. Research Laboratories and Institutions
13.5.2.3.2. Hospitals
13.5.2.3.3. Blood Banks
13.5.3. India
13.5.3.1. India Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.3.1.1. C1 esterase Inhibitors
13.5.3.1.2. Albumins
13.5.3.1.3. Immunoglobulins
13.5.3.1.4. Alpha-1 Proteinase Inhibitors
13.5.3.1.5. Coagulation Factors
13.5.3.1.6. Others
13.5.3.2. India Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.3.2.1. Alpha-1 Antitrypsin Deficiency
13.5.3.2.2. Hereditary Angioedema
13.5.3.2.3. Hemophilia
13.5.3.2.3.1. Hemophilia A
13.5.3.2.3.2. Hemophilia B
13.5.3.2.4. Primary Immunodeficiency Disorder
13.5.3.2.5. Antithrombin III Deficiency
13.5.3.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.3.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.3.2.8. Others
13.5.3.3. India Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.3.3.1. Research Laboratories and Institutions
13.5.3.3.2. Hospitals
13.5.3.3.3. Blood Banks
13.5.4. New Zealand
13.5.4.1. New Zealand Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.4.1.1. C1 esterase Inhibitors
13.5.4.1.2. Albumins
13.5.4.1.3. Immunoglobulins
13.5.4.1.4. Alpha-1 Proteinase Inhibitors
13.5.4.1.5. Coagulation Factors
13.5.4.1.6. Others
13.5.4.2. New Zealand Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.4.2.1. Alpha-1 Antitrypsin Deficiency
13.5.4.2.2. Hereditary Angioedema
13.5.4.2.3. Hemophilia
13.5.4.2.3.1. Hemophilia A
13.5.4.2.3.2. Hemophilia B
13.5.4.2.4. Primary Immunodeficiency Disorder
13.5.4.2.5. Antithrombin III Deficiency
13.5.4.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.4.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.4.2.8. Others
13.5.4.3. New Zealand Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1. Research Laboratories and Institutions
13.5.4.3.2. Hospitals
13.5.4.3.3. Blood Banks
13.5.5. Australia
13.5.5.1. Australia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.5.1.1. C1 esterase Inhibitors
13.5.5.1.2. Albumins
13.5.5.1.3. Immunoglobulins
13.5.5.1.4. Alpha-1 Proteinase Inhibitors
13.5.5.1.5. Coagulation Factors
13.5.5.1.6. Others
13.5.5.2. Australia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.5.2.1. Alpha-1 Antitrypsin Deficiency
13.5.5.2.2. Hereditary Angioedema
13.5.5.2.3. Hemophilia
13.5.5.2.3.1. Hemophilia A
13.5.5.2.3.2. Hemophilia B
13.5.5.2.4. Primary Immunodeficiency Disorder
13.5.5.2.5. Antithrombin III Deficiency
13.5.5.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.5.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.5.2.8. Others
13.5.5.3. Australia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1. Research Laboratories and Institutions
13.5.5.3.2. Hospitals
13.5.5.3.3. Blood Banks
13.5.6. South Korea
13.5.6.1. South Korea Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.6.1.1. C1 esterase Inhibitors
13.5.6.1.2. Albumins
13.5.6.1.3. Immunoglobulins
13.5.6.1.4. Alpha-1 Proteinase Inhibitors
13.5.6.1.5. Coagulation Factors
13.5.6.1.6. Others
13.5.6.2. South Korea Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.6.2.1. Alpha-1 Antitrypsin Deficiency
13.5.6.2.2. Hereditary Angioedema
13.5.6.2.3. Hemophilia
13.5.6.2.3.1. Hemophilia A
13.5.6.2.3.2. Hemophilia B
13.5.6.2.4. Primary Immunodeficiency Disorder
13.5.6.2.5. Antithrombin III Deficiency
13.5.6.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.6.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.6.2.8. Others
13.5.6.3. South Korea Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.6.3.1. Research Laboratories and Institutions
13.5.6.3.2. Hospitals
13.5.6.3.3. Blood Banks
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.7.1.1. C1 esterase Inhibitors
13.5.7.1.2. Albumins
13.5.7.1.3. Immunoglobulins
13.5.7.1.4. Alpha-1 Proteinase Inhibitors
13.5.7.1.5. Coagulation Factors
13.5.7.1.6. Others
13.5.7.2. Southeast Asia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.7.2.1. Alpha-1 Antitrypsin Deficiency
13.5.7.2.2. Hereditary Angioedema
13.5.7.2.3. Hemophilia
13.5.7.2.3.1. Hemophilia A
13.5.7.2.3.2. Hemophilia B
13.5.7.2.4. Primary Immunodeficiency Disorder
13.5.7.2.5. Antithrombin III Deficiency
13.5.7.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.7.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.7.2.8. Others
13.5.7.3. Southeast Asia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1. Research Laboratories and Institutions
13.5.7.3.2. Hospitals
13.5.7.3.3. Blood Banks
13.5.7.4. Southeast Asia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
13.5.8.1.1. C1 esterase Inhibitors
13.5.8.1.2. Albumins
13.5.8.1.3. Immunoglobulins
13.5.8.1.4. Alpha-1 Proteinase Inhibitors
13.5.8.1.5. Coagulation Factors
13.5.8.1.6. Others
13.5.8.2. Rest of Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.8.2.1. Alpha-1 Antitrypsin Deficiency
13.5.8.2.2. Hereditary Angioedema
13.5.8.2.3. Hemophilia
13.5.8.2.3.1. Hemophilia A
13.5.8.2.3.2. Hemophilia B
13.5.8.2.4. Primary Immunodeficiency Disorder
13.5.8.2.5. Antithrombin III Deficiency
13.5.8.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.5.8.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
13.5.8.2.8. Others
13.5.8.3. Rest of Asia Pacific Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1. Research Laboratories and Institutions
13.5.8.3.2. Hospitals
13.5.8.3.3. Blood Banks
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Therapies
13.6.3. By Indication
13.6.4. By End User
14. Middle East and Africa Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Middle East and Africa Plasma Protein Therapeutics Market Revenue (US$ Mn)
14.2. Middle East and Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.2.1. C1 esterase Inhibitors
14.2.2. Albumins
14.2.3. Immunoglobulins
14.2.4. Alpha-1 Proteinase Inhibitors
14.2.5. Coagulation Factors
14.2.6. Others
14.3. Middle East and Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.3.1. Alpha-1 Antitrypsin Deficiency
14.3.2. Hereditary Angioedema
14.3.3. Hemophilia
14.3.3.1. Hemophilia A
14.3.3.2. Hemophilia B
14.3.4. Primary Immunodeficiency Disorder
14.3.5. Antithrombin III Deficiency
14.3.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.3.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.3.8. Others
14.4. Middle East and Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1. Research Laboratories and Institutions
14.4.2. Hospitals
14.4.3. Blood Banks
14.5. Middle East and Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.1.1.1. C1 esterase Inhibitors
14.5.1.1.2. Albumins
14.5.1.1.3. Immunoglobulins
14.5.1.1.4. Alpha-1 Proteinase Inhibitors
14.5.1.1.5. Coagulation Factors
14.5.1.1.6. Others
14.5.1.2. Saudi Arabia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.1.2.1. Alpha-1 Antitrypsin Deficiency
14.5.1.2.2. Hereditary Angioedema
14.5.1.2.3. Hemophilia
14.5.1.2.3.1. Hemophilia A
14.5.1.2.3.2. Hemophilia B
14.5.1.2.4. Primary Immunodeficiency Disorder
14.5.1.2.5. Antithrombin III Deficiency
14.5.1.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.1.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.1.2.8. Others
14.5.1.3. Saudi Arabia Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1. Research Laboratories and Institutions
14.5.1.3.2. Hospitals
14.5.1.3.3. Blood Banks
14.5.2. UAE
14.5.2.1. UAE Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.2.1.1. C1 esterase Inhibitors
14.5.2.1.2. Albumins
14.5.2.1.3. Immunoglobulins
14.5.2.1.4. Alpha-1 Proteinase Inhibitors
14.5.2.1.5. Coagulation Factors
14.5.2.1.6. Others
14.5.2.2. UAE Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.2.2.1. Alpha-1 Antitrypsin Deficiency
14.5.2.2.2. Hereditary Angioedema
14.5.2.2.3. Hemophilia
14.5.2.2.3.1. Hemophilia A
14.5.2.2.3.2. Hemophilia B
14.5.2.2.4. Primary Immunodeficiency Disorder
14.5.2.2.5. Antithrombin III Deficiency
14.5.2.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.2.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.2.2.8. Others
14.5.2.3. UAE Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.2.3.1. Research Laboratories and Institutions
14.5.2.3.2. Hospitals
14.5.2.3.3. Blood Banks
14.5.3. Egypt
14.5.3.1. Egypt Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.3.1.1. C1 esterase Inhibitors
14.5.3.1.2. Albumins
14.5.3.1.3. Immunoglobulins
14.5.3.1.4. Alpha-1 Proteinase Inhibitors
14.5.3.1.5. Coagulation Factors
14.5.3.1.6. Others
14.5.3.2. Egypt Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.3.2.1. Alpha-1 Antitrypsin Deficiency
14.5.3.2.2. Hereditary Angioedema
14.5.3.2.3. Hemophilia
14.5.3.2.3.1. Hemophilia A
14.5.3.2.3.2. Hemophilia B
14.5.3.2.4. Primary Immunodeficiency Disorder
14.5.3.2.5. Antithrombin III Deficiency
14.5.3.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.3.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.3.2.8. Others
14.5.3.3. Egypt Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.3.3.1. Research Laboratories and Institutions
14.5.3.3.2. Hospitals
14.5.3.3.3. Blood Banks
14.5.4. Kuwait
14.5.4.1. Kuwait Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.4.1.1. C1 esterase Inhibitors
14.5.4.1.2. Albumins
14.5.4.1.3. Immunoglobulins
14.5.4.1.4. Alpha-1 Proteinase Inhibitors
14.5.4.1.5. Coagulation Factors
14.5.4.1.6. Others
14.5.4.2. Kuwait Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.4.2.1. Alpha-1 Antitrypsin Deficiency
14.5.4.2.2. Hereditary Angioedema
14.5.4.2.3. Hemophilia
14.5.4.2.3.1. Hemophilia A
14.5.4.2.3.2. Hemophilia B
14.5.4.2.4. Primary Immunodeficiency Disorder
14.5.4.2.5. Antithrombin III Deficiency
14.5.4.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.4.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.4.2.8. Others
14.5.4.3. Kuwait Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.4.3.1. Research Laboratories and Institutions
14.5.4.3.2. Hospitals
14.5.4.3.3. Blood Banks
14.5.5. South Africa
14.5.5.1. South Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.5.1.1. C1 esterase Inhibitors
14.5.5.1.2. Albumins
14.5.5.1.3. Immunoglobulins
14.5.5.1.4. Alpha-1 Proteinase Inhibitors
14.5.5.1.5. Coagulation Factors
14.5.5.1.6. Others
14.5.5.2. South Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.5.2.1. Alpha-1 Antitrypsin Deficiency
14.5.5.2.2. Hereditary Angioedema
14.5.5.2.3. Hemophilia
14.5.5.2.3.1. Hemophilia A
14.5.5.2.3.2. Hemophilia B
14.5.5.2.4. Primary Immunodeficiency Disorder
14.5.5.2.5. Antithrombin III Deficiency
14.5.5.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.5.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.5.2.8. Others
14.5.5.3. South Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.5.3.1. Research Laboratories and Institutions
14.5.5.3.2. Hospitals
14.5.5.3.3. Blood Banks
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.6.1.1. C1 esterase Inhibitors
14.5.6.1.2. Albumins
14.5.6.1.3. Immunoglobulins
14.5.6.1.4. Alpha-1 Proteinase Inhibitors
14.5.6.1.5. Coagulation Factors
14.5.6.1.6. Others
14.5.6.2. Rest of Middle East & Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.6.2.1. Alpha-1 Antitrypsin Deficiency
14.5.6.2.2. Hereditary Angioedema
14.5.6.2.3. Hemophilia
14.5.6.2.3.1. Hemophilia A
14.5.6.2.3.2. Hemophilia B
14.5.6.2.4. Primary Immunodeficiency Disorder
14.5.6.2.5. Antithrombin III Deficiency
14.5.6.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
14.5.6.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
14.5.6.2.8. Others
14.5.6.3. Rest of Middle East & Africa Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1. Research Laboratories and Institutions
14.5.6.3.2. Hospitals
14.5.6.3.3. Blood Banks
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Therapies
14.6.3. By Indication
14.6.4. By End User
15. Latin America Plasma Protein Therapeutics Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn)
15.2. Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
15.2.1. C1 esterase Inhibitors
15.2.2. Albumins
15.2.3. Immunoglobulins
15.2.4. Alpha-1 Proteinase Inhibitors
15.2.5. Coagulation Factors
15.2.6. Others
15.3. Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
15.3.1. Alpha-1 Antitrypsin Deficiency
15.3.2. Hereditary Angioedema
15.3.3. Hemophilia
15.3.3.1. Hemophilia A
15.3.3.2. Hemophilia B
15.3.4. Primary Immunodeficiency Disorder
15.3.5. Antithrombin III Deficiency
15.3.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.3.7. Idiopathic Thrombocytpenic Purpura (ITP)
15.3.8. Others
15.4. Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.4.1. Research Laboratories and Institutions
15.4.2. Hospitals
15.4.3. Blood Banks
15.5. Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
15.5.1.1.1. C1 esterase Inhibitors
15.5.1.1.2. Albumins
15.5.1.1.3. Immunoglobulins
15.5.1.1.4. Alpha-1 Proteinase Inhibitors
15.5.1.1.5. Coagulation Factors
15.5.1.1.6. Others
15.5.1.2. Brazil Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.1.2.1. Alpha-1 Antitrypsin Deficiency
15.5.1.2.2. Hereditary Angioedema
15.5.1.2.3. Hemophilia
15.5.1.2.3.1. Hemophilia A
15.5.1.2.3.2. Hemophilia B
15.5.1.2.4. Primary Immunodeficiency Disorder
15.5.1.2.5. Antithrombin III Deficiency
15.5.1.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.5.1.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
15.5.1.2.8. Others
15.5.1.3. Brazil Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1.3.1. Research Laboratories and Institutions
15.5.1.3.2. Hospitals
15.5.1.3.3. Blood Banks
15.5.2. Argentina
15.5.2.1. Argentina Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
15.5.2.1.1. C1 esterase Inhibitors
15.5.2.1.2. Albumins
15.5.2.1.3. Immunoglobulins
15.5.2.1.4. Alpha-1 Proteinase Inhibitors
15.5.2.1.5. Coagulation Factors
15.5.2.1.6. Others
15.5.2.2. Argentina Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.2.2.1. Alpha-1 Antitrypsin Deficiency
15.5.2.2.2. Hereditary Angioedema
15.5.2.2.3. Hemophilia
15.5.2.2.3.1. Hemophilia A
15.5.2.2.3.2. Hemophilia B
15.5.2.2.4. Primary Immunodeficiency Disorder
15.5.2.2.5. Antithrombin III Deficiency
15.5.2.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.5.2.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
15.5.2.2.8. Others
15.5.2.3. Argentina Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.2.3.1. Research Laboratories and Institutions
15.5.2.3.2. Hospitals
15.5.2.3.3. Blood Banks
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Therapies
15.5.3.1.1. C1 esterase Inhibitors
15.5.3.1.2. Albumins
15.5.3.1.3. Immunoglobulins
15.5.3.1.4. Alpha-1 Proteinase Inhibitors
15.5.3.1.5. Coagulation Factors
15.5.3.1.6. Others
15.5.3.2. Rest of Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.3.2.1. Alpha-1 Antitrypsin Deficiency
15.5.3.2.2. Hereditary Angioedema
15.5.3.2.3. Hemophilia
15.5.3.2.3.1. Hemophilia A
15.5.3.2.3.2. Hemophilia B
15.5.3.2.4. Primary Immunodeficiency Disorder
15.5.3.2.5. Antithrombin III Deficiency
15.5.3.2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
15.5.3.2.7. Idiopathic Thrombocytpenic Purpura (ITP)
15.5.3.2.8. Others
15.5.3.3. Rest of Latin America Plasma Protein Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1. Research Laboratories and Institutions
15.5.3.3.2. Hospitals
15.5.3.3.3. Blood Banks
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Therapies
15.6.3. By Indication
15.6.4. By End User
16. Competitive Benchmarking
16.1. Market Share Analysis, 2021
16.2. Global Presence and Growth Strategies
16.2.1. Mergers and Acquisitions
16.2.2. Product Launches
16.2.3. Investments Trends
16.2.4. R&D Initiatives
17. Player Profiles
17.1. ADMA Biologics, Inc.
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Baxter International
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Biotest
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. China Biologics
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. CSL
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. GRIFOLS, S.A.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Kedrion
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Octapharma AG
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Takeda Pharmaceutical Company Ltd
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Other market participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.